CDK2 and melanoma: MiR-211 changed the ability of melanocyte migration ability by targeting matrix metalloproteinase 9; therefore, CKS2 may be a therapeutic target to improve repigmentation in vitiligo patients.[15] Previous studies have found that with the upregulation of CKS2, the mRNA of CDK2/4/6 proteins inhibited by the P21 protein gradually increased,[14] and CDK2 was involved in the development of melanoma by regulating the G1/S and G2 phases of the cell cycle.[16] Similarly, melanocyte loss due to the abnormal expression of CDK2 was observed in vitiligo patients, but the exact mechanism is unclear.[17]